Clinical trial
A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study
NCT04456959 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Retrospective Chart Review of UK Patients With Relapsed/Refractory Acute Lymphoblastic Leukaemia Treated With Inotuzumab Ozogamicin, a Real World Research Study
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 6, 2020
- Completion date
- January 27, 2021
- Enrollment
- 28 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.